Unlocking the potential:advancements and future horizons in ROR1-targeted cancer therapies

作     者：Lin Li Weixue Huang Xiaomei Ren Zhen Wang Ke Ding Linxiang Zhao Jinwei Zhang 

作者机构：State Key Laboratory of Structure-Based Drugs Design&Discovery of Ministry of EducationShenyang Pharmaceutical University State Key Laboratory of Chemical BiologyResearch Center of Chemical KinomicsShanghai Institute of Organic ChemistryChinese Academy of Sciences 

出 版 物：《Science China Life Sciences》 (中国科学:生命科学(英文版))

年 卷 期：2024年

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

摘      要：While receptor tyrosine kinase-like orphan receptor 1 (ROR1) is typically expressed at low levels or absent in normal tissues,its expression is notably elevated in various malignant tumors and conditions,including chronic lymphocytic leukemia (CLL),breast cancer,ovarian cancer,melanoma,and lung *** distinctive feature positions ROR1 as an attractive target for tumor-specific ***,several targeted drugs directed at ROR1 are undergoing clinical development,including monoclonal antibodies,antibody-drug conjugates (ADCs),and chimeric antigen receptor T-cell therapy (CAR-T).Additionally,there are four small molecule inhibitors designed to bind to ROR1,presenting promising avenues for the development of PROTAC degraders targeting *** review offers updated insights into ROR1’s structural and functional characteristics,embryonic development implications,cell survival signaling pathways,and evolutionary targeting strategies,all of which have the potential to advance the treatment of malignant tumors.